Research and Markets has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2016" report to their offering.
Cedar Pollen Allergy pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Cedar Pollen Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Treatment includes antihistamines and decongestants. The molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/2ph7k6/cedar_pollen
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006433/en/Business Wire
Last updated on: 27/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.